title: Anti-Ku antibody-positive scleroderma-dermatomyositis overlap syndrome developing Graves' disease and immune thrombocytopenic purpura.
abstract: Graves' disease (GD) has been reported to be frequently complicated with other autoimmune diseases. However, it is rarely complicated with scleroderma-polymyositis overlap syndrome. Recently, we encountered a 35-year-old woman who developed GD and immune thrombocytopenic purpura during follow-up observation of scleroderma-dermatomyositis overlap syndrome. Platelet counts recovered after high-dose gamma-globulin therapy and bolus methylprednisolone therapy. The present case is the first report of a combination of scleroderma, dermatomyositis, GD, and immune thrombocytopenic purpura. The patient was anti-Ku antibody-positive and had relatively low natural killer T cell counts, both of which might contribute to the complication of multiple autoimmune diseases.
authors.affiliation: Department of Molecular and Internal Medicine, Division of Clinical Medical Science, Programs for Applied Biomedicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima.
authors.forename: Nozomu
authors.initials: N
authors.lastname: Kamei
authors.forename: Kiminori
authors.initials: K
authors.lastname: Yamane
authors.forename: Yasuyo
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Shuhei
authors.initials: S
authors.lastname: Nakanishi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Watanabe
authors.forename: Rumi
authors.initials: R
authors.lastname: Fujikawa
authors.forename: Keiko
authors.initials: K
authors.lastname: Hiyama
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ishioka
authors.forename: Ciro
authors.initials: C
authors.lastname: Mendoza
authors.forename: Nobuoki
authors.initials: N
authors.lastname: Kohno
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D034961:Antigens, Nuclear / Q000276:immunology*; D013956:Antithyroid Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood*; D004265:DNA Helicases; D004268:DNA-Binding Proteins / Q000276:immunology*; D003882:Dermatomyositis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006111:Graves Disease / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D000072200:Ku Autoantigen; D008713:Methimazole / Q000627:therapeutic use; D017713:Platelet Transfusion; D011441:Propylthiouracil / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications* / Q000276:immunology / Q000628:therapy; D012595:Scleroderma, Systemic / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D013256:Steroids
chemical_list: D000893:Anti-Inflammatory Agents; D034961:Antigens, Nuclear; D013956:Antithyroid Agents; D001323:Autoantibodies; D004268:DNA-Binding Proteins; D013256:Steroids; D008713:Methimazole; D011441:Propylthiouracil; D004265:DNA Helicases; C106893:XRCC5 protein, human; C000606509:Xrcc6 protein, human; D000072200:Ku Autoantigen